Heart Health Simplified: Expert Tips That Work | Dr Christie Ballantyne

Ballantyne has measured Lp(a) in his clinic since starting at Baylor in 1997 — well ahead of mainstream adoption. He explains: if a patient has Lp(a) of 3,150 nmol/L and a strong family history, that completely changes the risk conversation even if the LDL seems manageable. If Lp(a) is low (desirable range), it stays low for life and need not be repeated. The Gray Zone (75-125 nmol/L) is where repeat testing at major life transitions matters.

Ballantyne argues non-HDL should have been the standard metric all along — it should have been called 'atherogenic cholesterol.' The naming failure is itself a patient safety issue: patients hear 'non-HDL' and think it means 'not the dangerous one.' In practice, non-HDL is a better single predictor of cardiovascular events than LDL cholesterol and is essentially as informative as apoB for the majority of patients.

Ballantyne worked on studies with Dr. Donna Layman at the University of Illinois. Reducing carbohydrates to ≤130g/day 'completely normalized' triglycerides in their trials. He contrasts this with LDL, which is far less diet-sensitive: 'triglycerides we can see dramatic changes — I mean someone can go from 5,000 down to 200 with changes in lifestyle and that can happen within 10 days.'

Ballantyne references the CLEAR trial of bempedoic acid — the first large cardiovascular outcomes trial to enroll equal numbers of men and women, specifically because statin-intolerant patients skew female. He notes that even 5 mg of lovastatin is no longer used because the dose-response is subtherapeutic, but starting rosuvastatin 2.5 mg three times a week is a viable entry point for the most intolerant patients.

Ballantyne explicitly rejects the medical culture of recommending only 30-minute walks and 10,000 steps: 'there's no sense acting like optimal is walking 30 minutes five times a week — it is not optimal. We don't use 5 mg of lovastatin any more either.' He personally does one hour per day combining resistance and cardiovascular work. He identifies resistance training as especially important for GLP-1 patients: the muscle loss from these drugs without resistance training is a 'frailty setup' for older patients.

Ballantyne notes that EPA is involved with resolution of inflammation — resolvins and related biochemical derivatives — which is probably the mechanism for the cardiovascular benefit beyond triglyceride lowering. He cautions patients who read the label of their OTC fish oil supplement: '1,000 mg capsule' usually contains only 300 mg of EPA+DHA. To reach the therapeutic dose of 4g of EPA+DHA from OTC capsules, you would need to take 14 large capsules daily — the prescription generic is more practical at 2 grams twice daily.

Ballantyne describes a paradigm shift from his residency days at UT Southwestern, where residents were taught to maximally dose one drug before adding a second — resulting in toxic dose-response effects (hypokalemia from hydrochlorothiazide 50 mg twice daily, extreme side effects from clonidine). Combination therapy at low doses of two agents now achieves better control with fewer side effects. The same principle applies to lipid management: low-dose statin + ezetimibe beats maximal statin dosing in tolerability.

Ballantyne notes the historical parallel with diabetes outcomes trials: for years, no one would run them after a large early failure (University Drug Project). The WHI for HRT had the same chilling effect. Now the Lp(a) field has enough mechanistic evidence (it is pro-inflammatory, pro-thrombotic, drives aortic valve calcification, and elevates coronary atherosclerosis and peripheral arterial disease risk) that FDA has signaled willingness to accept cardiovascular event reduction as the primary endpoint in the siRNA trials currently enrolling.

The residual 5% of discordance between non-HDL and apoB matters most in patients with elevated triglycerides: those patients have lots of small, dense LDL particles that carry an apoB but relatively little cholesterol — so non-HDL underestimates particle burden. This is where the apoB (and NMR particle size testing from LabCorp or Boston Heart) adds genuine incremental signal. But for the median patient with normal-range triglycerides, non-HDL is essentially equivalent and costs nothing extra.

The clinical translation: a patient with a fasting triglyceride of 130 mg/dL but HDL of 32 is telling you something very different from a patient with TG 130 and HDL of 62 — the first patient's postprandial clearance is likely poor, their particle burden after meals is high, and their risk equation is substantially worse than the fasting lipid panel suggests. This is one reason Ballantyne prefers the full lipid panel as the first screening test rather than jumping straight to apoB.

Ballantyne explains that obesity-driven insulin resistance triggers inflammation, endothelial dysfunction, and atherogenic dyslipidemia (high triglycerides, low HDL, small dense LDL) that can drive the same arterial damage as very high LDL or cigarettes — even when the standard lipid panel looks acceptable. The key markers to add to catch this: triglycerides, HDL, waist circumference, and hemoglobin A1c.

Women also have higher rates of statin intolerance, more Lp(a) elevation post-menopause, more joint pain from lipid-modifying hormonal changes, and higher rates of autoimmune disease that confounds symptom interpretation. Ballantyne's prescription: treat cardiovascular risk in women at least as aggressively as in men, try multiple statins and combination therapies rather than giving up, and recognize that premenopausal 'protection' can vanish rapidly at menopause.

Ballantyne references a Copenhagen trial showing that patients on GLP-1s who committed to lifestyle change were able to reduce their dose and in some cases stop. He specifies: any patient on a GLP-1 must combine the drug with resistance training and protein-forward nutrition to preserve lean mass. This converges with Lyon's entire clinical framework around muscle as the longevity organ.